Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Nutranomics, Inc.
DRAPER, Utah, Oct. 23, 2013 /PRNewswire/ -- Nutranomics, Inc. (OTCBB: NNRX) (OTCQB: NNRX) ("Nutranomics" or the "Company") is pleased to report that the Company has received an additional purchase order from Buildmore Enterprise Co, Ltd. ("Buildmore"), a health food supplement contract manufacturing and distribution company located in Taipei City, Taiwan.
The purchase order for 100 kilograms of the Nutranomics' patented AES (Assimilation Enhancing System) compound, a proprietary formulation developed by Nutranomics founder and CEO, Dr. Tracy Gibbs, is expected to be added to existing Buildmore manufactured dietary supplements to enhance their bioavailability and/or absorption.
"Buildmore has been a good and steady client of Nutranomics for the past six years. This additional order for our patented AES formulation demonstrates that, in addition to new customer growth, there are still potential opportunities for our Company to expand sales within our current customer base," stated Mr. Amar Chandnani, Asia Area Director of Nutranomics. "Based on our discussions with Buildmore management, we expect that the Nutranomics AES formulation will be blended into various branded supplements sold by Buildmore within the Taiwan market."
Nutranomics is a publicly traded company engaged in research and development of nutritional food products. In 1997, Nutranomics produced and branded its own product line, and began to sell to the retail outlets and to the public. Nutranomics has also produced formulas for hundreds of other companies. Nutranomics' mission is to increase human health and longevity through education and self-awareness. The Company has sales representatives throughout North America and Asia.
For further information regarding Nutranomics, Inc., please contact our investor relations representatives at firstname.lastname@example.org or call toll-free (888) 616-3999.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements." Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include the Company's plan to execute and accelerate its global sales and marketing plans. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products and operating as a development stage company, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by applicable law, including the securities laws of the United States. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.
©2012 PR Newswire. All Rights Reserved.